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 3 
Abstract  
 
Antibiotic resistance has increased for many different diseases including tuberculosis. 
Scientists have begun to seek ways and places to discover new antibiotics to combat this 
resistance. Studies over the last 60 years suggest that pathogen-inhibiting bacteria can be found 
in soil. A number of bacterial isolates potentially producing antibiotic compounds have been 
found in the soil by students in the Microbes to Molecules laboratory course at Worcester 
Polytechnic Institute (WPI). This project tested those isolates for the ability to inhibit the growth 
of Mycobacterium smegmatis, a model bacteria for Mycobacterium tuberculosis. The goal of the 
project described here was to identify isolates capable of inhibiting M. smegmatis and determine 
the mechanism(s) of inhibition.  
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Introduction 
 
Although tuberculosis (TB) is rare in the United States, it is thought to exist in its latent 
form in about one third of the world's population. 10.4 million new cases of TB were reported in 
2015 (World Health Organization, 2015). The bacteria is known as a “crowd” pathogen because 
it can be easily spread from an infected person to an uninfected person through aerosols (Barbier, 
2016). Once the bacteria enters the body, it enters the lungs and begins to grow and spread.  
Drug resistance is a major problem for patients with TB. Drug resistance occurs when 
sensitive bacteria acquire mutations in drug targets, genes encoding enzymes required for 
prodrug activation, or genes controlling drug efflux (Calligaro, 2013). Prolonged use of 
antibiotics is associated with increased likelihood that drug-resistant bacteria will emerge 
(Calligaro, 2013). Resistance may occur if individuals fail to complete a course of antibiotics. 
This is particularly problematic in the case of TB, which requires a minimum of six months of 
multidrug treatment. Adherence to such a long regimen is challenging in the face of potentially 
serious side effects and inconsistent access to drugs in the resource-limited settings where TB is 
most prevalent. Other reasons for the rise in drug resistant forms include delays in treatment, 
inadequate space for doctors to treat people, and poor infection control (Calligaro, 2013).  
TB is treated with antibiotic combinations in order to simultaneously target multiple bacterial 
functions, decreasing the probability of acquiring resistance. Ethambutol, isoniazid, rifampin, 
and pyrazinamide are the four first-line drugs used to treat drug-sensitive tuberculosis by 
targeting different cellular aspects of M. tuberculosis. Ethambutol obstructs the synthesis of the 
cell wall (Silve, 1993). Isoniazid also targets synthesis of the cell wall (Rozwarski, 1998). 
Rifampin targets RNA polymerase, blocking transcription (Wang, 2013). As resistance to these 
drugs becomes more prevalent, there is a need for new drugs with different targets.  
Mycobacterium smegmatis is frequently used as a non-pathogenic model for M. 
tuberculosis. Like M. tuberculosis, it is aerobic, gram-variable, and nonmotile. M. smegmatis 
was first reported in 1884 by Lustgarten, who was studying syphilis chancres and found a 
bacillus with the staining appearance of tuberculosis bacilli. It is also present in soil around the 
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globe.  Like M. tuberculosis, M. smegmatis protects itself with a lipid outer membrane that is 
distinct in composition from the outer membranes of gram-negative bacteria. It has very low 
permeability, conferring intrinsic resistance to many antibiotics. M. smegmatis grows much more 
quickly than M. tuberculosis, forming colonies on plates in three days (Akinola, 2013). The fast 
growth rate and non-pathogenic nature of M. smegmatis make it a useful model organism. 
The purpose of this project was to find novel compounds produced by other bacteria that 
have potential to be used as antibiotics for tuberculosis. M. smegmatis was used as a safe model 
for identifying potential inhibitors of M. tuberculosis that are produced by bacteria isolated from 
soil.  The bacterial isolates were found in the soil by students in the Microbes to Molecules 
course (part of the Small World initiative, which is trying to solve the worldwide health issue of 
antibiotic resistance by using crowdsourcing) during the spring terms of 2014-2016. The 
interactions between the soil isolates and M. smegmatis were studied to find which of the isolates 
had antimicrobial activity against M. smegmatis. We then attempted to identify a subset of the 
isolates through the use of two different PCR protocols and sequencing. Additionally, we found 
that an acellular extract of one of the isolates had antimicrobial activity against M. smegmatis. 
The ultimate goals for future research will be to identify the compound and discover the 
mechanism by which inhibition occurs.  This will allow us to determine if we have isolated a 
bacteria producing an antibiotic that belongs to a new class and inhibits via a new mechanism. 
Materials and Methods  
General methods 
We collected and cataloged all soil isolates given to us by an introductory biology lab 
course taught on campus known as “Microbes to Molecules”. This lab was successful in isolating 
75 bacterial isolates from local soils over the course of three years (2014-2016), which we used 
to begin our experiments. All isolates were previously stored in a -80°C freezer in 1 mL liquid 
aliquots.  
Petri dishes containing luria broth (LB) agar gel were made (Appendix B) in order to 
grow and store the M. smegmatis and bacterial isolates. LB agar was chosen as the growth 
medium for M. smegmatis and the bacterial isolates because it is a nutrient rich media that 
supports the growth of a wide variety of bacteria. 
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Bacterial Isolates culture 
The soil isolates were previously patched on a gridded LB agar plate from the liquid 
aliquots by another group of students working with the isolates, allowed to grow into a master 
plate, and made available for use in experimentation. In order to have enough bacteria for 
experimentation, both the M. smegmatis and soil isolates were moved onto separate prepared LB 
plates and allowed to grow. A flame-sterilized inoculation loop was used to move small samples 
of each of the 75 soil isolates from the gridded agar plates to our prepared agar plates, and the 
loop was flame sterilized between each bacteria spread. These plates were incubated in a 37°C 
incubator for 3 days to allow for bacterial spread and growth, and then moved into a 4°C 
refrigerator until needed for experimentation. See Appendix C for a more detailed protocol. 
 
Mycobacterium smegmatis culture 
M. smegmatis strain mc2155 was provided by our advisor, Scarlet Shell. We grew a liquid 
culture to make frozen aliquots (Appendix D) for experimentation. We chose to use Middlebrook 
7H9 Broth with Tween as the liquid growth medium, as several published protocols suggested 
that this combination of media allows mycobacteria, especially M. smegmatis and M. 
tuberculosis, to flourish and grow successfully. Liquid cultures were grown at 37°C with shaking 
and frozen at an optical density (OD) of 0.7.  Aliquots were stored in a -80°C freezer. 
 
 
Isolate testing 
  To determine which of the 75 soil isolates had the ability to inhibit the growth of M. 
smegmatis, each isolate was plated together with M. smegmatis (Appendix E). LB agar plates 
were spread with 200µl each of the liquid M. smegmatis that was grown to an OD of 0.7 and 
allowed to dry for 5 minutes. Once dry, a flame sterilized inoculation loop was used to lift 
colonies of the soil isolates from the stock plates and spread on top of the dried M. smegmatis. 
These plates were then incubated at 37°C for 3 days.  
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Of the isolates that did inhibit the growth of M. smegmatis, four of them were chosen to 
continue research on. To discover if any of these four bacteria created secretions that have 
antimicrobial properties, a methanol extraction was performed (Appendix J). This was done by 
creating individual plates of each bacteria with thick lawns covering almost all of the plate. The 
bacteria-covered agar was then cut and placed in 50 mL conical tubes. The tubes were then 
placed in liquid nitrogen for 5 minutes. After the tubes had frozen, the 12 mL of methanol was 
added and then the tubes were left to shake at room temperature overnight. The liquid was then 
extracted from each tube using a pipette aid and placed in vials that were left open so that the 
methanol would evaporate off in a hood. Once ready to plate the extractions were redissolved in 
1 mL of methanol and 30ul was applied to a filter disk and allowed to dry for 2 minutes before 
being placed on LB agar plates that had been spread with 200 µl of M. smegmatis at an OD of 
0.7 and allowed to dry for five minutes.   
 
Isolate Identification 
In order to identify these four bacteria, colony PCR was performed with forward primer 
27F and reverse primer 1492R for all the isolates except 2014-3 where forward primer sss969 
and reverse primer sss967 were used according to the detailed protocol outlined in Appendix F. 
The sequence for these four primers can be seen in table 1. For these bacterial isolates it was 
found that DNA extraction (Appendix G) followed by PCR (Appendix H) created better products 
for sequencing. PCR products were analyzed by gel electrophoresis (Appendix I) using 1% 
agarose gel, hyperladder marker, and SYBR green. 
Table 1: sequence of primers used for PCR 
Primer Primer sequence 
27F AGAGTTTGATCMTGGCTCAG 
1492R TACGGYTACCTTGTTACGACTT 
sss967 TACCTTGTTACGACTT 
sss969 AGGGTTCGATTCTGGCTCAG 
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The PCR products that produced visible bands on the gels were sent to Eton Biosciences 
to be purified and sequenced. The sequence files were opened with a program called “4Peaks” 
and the ends with lower quality sequencing were trimmed. The remaining sequence was used as 
a query to search the NCBI nucleotide database using BLASTn. Matches with 99% identity were 
considered to be the most possible identities of the isolates. In cases where there was not 99% 
identity, the DNA was extracted again and a new PCR run to try to get better quality results. 
 
Results  
  
         To find soil isolates capable of inhibiting the growth of M. smegmatis, we patched 75 
previously banked bacterial isolates (appendix A) on plates spread with liquid cultures of M. 
smegmatis. Fourteen of the bacteria inhibited M. smegmatis growth. Of the fourteen isolates, 
seven were from the year 2014, five were from 2015, and two were from 2016. These plates can 
be seen in figures 1 through 14 below with blue arrows pointing to the zones of inhibition 
surrounding the patch of soil isolate in the center of the plate. Four isolates that were distinct in 
color, colony growth pattern, and zone sizes were chosen for further study. Figures 3, 8, 9, and 
13 show the different zone sizes, colors and colony growth patterns observed for the isolates that 
were chosen: 2014-3, 2015-1, 2015-27, and 2016-16. 
    
Figure 1: isolate 2014-1 plated on LB  Figure 2: Isolate 2014-2 plated on LB 
 with M. smegmatis     with M. smegmatis 
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Figure 3: isolate 2014-3 plated on LB  Figure 4: Isolate 2014-14 plated on LB  
 with M. smegmatis     with M. smegmatis 
   
Figure 5: isolate 2014-16 plated on LB  Figure 6: Isolate 2014-17 plated on LB 
 with M. smegmatis     with M. smegmatis 
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Figure 7: isolate 2014-26 plated on LB  Figure 8: Isolate 2015-1 plated on LB 
 with M. smegmatis     with M. smegmatis 
    
Figure 9: isolate 2015-27 plated on LB  Figure 10: Isolate 2015-28 plated on LB 
 with M. smegmatis     with M. smegmatis 
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Figure 11: isolate 2015-32 plated on LB  Figure 12: Isolate 2015-56 plated on LB  
 with M. smegmatis     with M. smegmatis 
    
Figure 13: isolate 2016-16 plated on LB  Figure 14: Isolate 2016-22 plated on LB 
 with M. smegmatis     with M. smegmatis 
 
We then attempted to identify isolates 2015-1, 2014-3, 2016-16, and 2015-27 by colony 
PCR using the 27F forward primer with 1492R reverse primer to amplify the 16S rRNA gene 
followed by sequencing. Two isolates, 2014-3 and 2016-16, produced bands between 1000 and 
1500 base pairs which is expected as the product should be about 1500 base pairs, while the 
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other two isolates did not produce any visible bands (figure 15). The sequencing (done by Eton 
Bioscience) returned sequences of low quality which did not show homology to any known 
sequences in the database. This process was repeated twice with similar sequencing results that 
did not match any sequences in the 16S rRNA database.  
 
 
 
Figure 15: Analysis of colony PCR by gel electrophoresis. 
As multiple attempts at colony PCR failed to produce bands and high quality sequencing 
data, DNA was extracted from colonies from streak plates of the bacteria and amplified using the 
27F forward primer with 1492R reverse primer and sss969 forward primer with sss967 reverse 
primer. The second set of primers, sss969/sss967, was used as an attempt to get better 
sequencing results. Isolates 2015-1 and 2016-16 produced bands higher than the expected size of 
 13 
approximately 1500 base pairs when primers 27F and 1492R were used, and 2014-3 also 
produced a band higher than the expected size when primers sss967 and sss969 were used 
(Figure 16). 
   
Figure 16: Gel electrophoresis of PCR performed on purified DNA with two sets of primers 
 
In a further attempt to obtain a PCR product from isolate 2015-27, we repeated the DNA 
extraction and subject it to PCR with primer sets 27F/1492R and sss967/sss969. We also used 
these primer sets to re-amplify the product from the PCR shown in figure 16. The PCR using the 
newly extracted DNA with 27F/1492R produced the clearest band (Figure 17). The size of the 
band was unclear because the ladder was not clearly visualized.  
 The PCR products that produced the clearest bands on the gels in Figures 16 and 17 
(indicated with stars) were then sequenced with primers 27F and 1492R for 2015-1, 2016-16, 
2015-27 and primers sss967 and sss969 for 2014-3. NCBI’s blast program revealed that both 
2015-1 and 2014-3 show 99-98% identity over the longest stretch of sequencing with multiple 
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members of the genus Bacillus.  Isolate 2016-16 appears to be either Enterobacter or Raoultella 
as both of these genera matched with 99% identity over long stretches of the sequence (95% and 
above). The 2015-27 sequencing data quality was too poor to obtain meaningful blast hits (Table 
1). The sequences done with the primers 27F and sss967 can be seen in Appendix K. 
  
Figure 17: Analysis of PCR products obtained from isolate 2015-27. 
 
 
Table 1: Isolate identities 
Isolate tag 2014-3 2015-1 2015-27 2016-16 
Probable genus Bacillus Bacillus Unknown Enterobacter  or 
Raoultella 
 
The initial goal of the project was to identify isolates that inhibited M. smegmatis by 
secretion of an inhibitory substance and not just by depletion of nutrients from the surrounding 
media. To assess the presence of inhibitory substances, we performed organic extractions on the 
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putative antibiotic producing isolates and tested the abilities of these extracts to inhibit growth of 
M. smegmatis. Extracts were applied to filter disks and overlaid on plates spread with M. 
smegmatis. As a positive control, rifampin diluted in DMSO and plated at three different 
concentrations inhibited growth of M. smegmatis as expected (Figure 18). The two negative 
controls DMSO (the solvent for rifampin) and methanol (the solvent for the extracts) failed to 
inhibit growth as expected (Figure 19). Extracts of isolates 2014-3, 2015-1, and 2016-16 showed 
no inhibition of M. smegmatis growth (Figures 20 and 21). However, an extract of isolate 2015-
27 shows a clear zone of inhibition, suggesting that this organism either secretes or contains a 
methanol-soluble molecule capable of inhibiting the growth of M. smegmatis (Figure 21). Blue 
arrows point to the zones that were created by 2015-27 and rifampin. In several cases, including 
the DMSO control, a ring of bacterial growth was observed around the edge of the filter disk. 
This appears to be a contaminant. We therefore cannot exclude the possibility that inhibition 
observed for the isolate 2015-27 extract was due to the contaminant rather than the extract.  
 
Figure 18: M. smegmatis spread on LB and overlaid with filter disks to which 30 ul of rifampin 
at concentrations of 50 mg/ml, 10 mg/ml, and 1 mg/ml were applied.  
 16 
 
Figure 19:  30ul of DMSO or methanol was applied to filter disks that were overlaid on an LB 
plate spread with M. smegmatis as negative controls.  
 
Figure 20:  30 ul of methanol extracts of isolates 2014-3 and 2016-16 where applied to filter 
disks and overlaid on LB plates spread with M. smegmatis.  
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Figure 21: 30 ul of methanol extracts of isolates 2015-1 and 2015-27 where applied to filter disks 
and overlaid on LB plates spread with M. smegmatis.  
 
Discussion  
The purpose of this project was to identify bacterial isolates from a pool of potential 
producers already isolated by the 2014-2016 Microbes to Molecules classes that show activity 
against M. smegmatis. Our plating of M. smegmatis in combination with the isolates taken from 
the “Microbes to Molecules” laboratory identified 14 isolates with inhibitory abilities. While this 
showed that these isolates could inhibit M. smegmatis, we then went a step further in order to 
identify these isolates and demonstrate that they were truly antimicrobial, and not just inhibiting 
growth by nutrient deprivation or similar mechanisms. To do this we chose four of the inhibiting 
isolates that seemed to have different properties from each other in order to ensure that we would 
not be testing the same species four times.  
 An extraction was performed on all four isolates in order to see if any contained or 
secreted substances capable of inhibiting M. smegmatis growth. Only 2015-27, the unidentified 
isolate, produced an extract that inhibited the growth of M. smegmatis. Extracts from the other 
three isolates did not produce any zone of inhibitions. 
DNA extraction resulted in all four isolates producing PCR products that showed bands 
by gel electrophoresis. When sent out for sequencing, three out of the four isolates (2014-3, 
2015-1, and 2016-16) returned high-quality sequences. 2014-3 and 2015-1 were concluded to be 
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species of Bacillus; 2016-16 was found to have an equal chance of being a species of 
Enterobacter or Raoultella, while 2015-27 returned only poor quality sequencing results. We 
speculate that 16S rRNA sequence of isolate 2015-27 differs at the locations where our primers 
anneal, resulting in poor annealing and poor quality sequence. Future efforts to identify this 
isolate could include designing and testing new primers for isolate 2015-27, perhaps based on the 
short stretches of sequence obtained that were of high enough quality to be interpretable. 
Biochemical tests, such as the triple sugar iron test or starch hydrolysis test, can be used to help 
find the best matching similar bacteria to guide creation of different primers. Identification of the 
2015-27 bacteria would also be necessary to confirm that it is non-pathogenic and therefore safe 
enough to use for future research that involved liquid culture. 
Future efforts should also focus on identifying the inhibitory substance produced by 
isolate 2015-27. These efforts could include fractionation of the extracts and identification of the 
components of inhibitory fractions by high performance liquid chromatography (HPLC) and 
mass spectrometry. The extract would also need to be tested against M. tuberculosis to see if its 
components have active antimicrobial behavior against it. Using the antimicrobial components of 
the extracts to select for resistant M. smegmatis would potentially allow for identification of the 
antibiotic target by using comparative sequencing of sensitive and resistant strains.  
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Appendix A: tables of information on isolates 
Table 1: isolate information from 2014 
Number Genus Description Did it inhibit 
M. smegmatis? 
1 Unknown Medium yellow, small round colonies yes 
2 Unknown Yellow/white, colony all together on plate, smooth yes 
3 Bacillus White, medium sized round colonies, smooth yes 
4 Unknown Medium yellow, medium round colonies no 
5 Unknown Grows extremely quickly. Looks like a singular white/yellow 
colony but could be very large colonies grouped together 
no 
6 Unknown none given no 
8 Unknown none given no 
11 Unknown none given no 
12 Unknown none given no 
13 Unknown none given no 
14 Unknown white, small round colonies yes 
15 Unknown Grows extremely quickly. Looks like a singular white/yellow 
colony but could be very large colonies grouped together 
no 
16 Unknown White, small rod shaped colonies yes 
17 Unknown White/yellow, small round colonies yes 
19 Unknown White, medium round colonies no 
20 Unknown White/yellow, looks like singular colony but might be small rod 
shaped colonies 
no 
21 Unknown none given no 
22 Unknown none given no 
23 Unknown none given no 
24 Unknown none given no 
26 Unknown White round colonies yes 
27 Unknown none given no 
29 Unknown none given no 
Table 2: Isolate information from 2015 
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Number Genus Description Did it inhibit M. 
smegmatis? 
1 Bacillus Medium yellow rod shaped colonies yes 
2 Unknown White/yellow small round colonies no 
3 Unknown White rod shaped colonies no 
4 Unknown none given no 
5 Unknown none given no 
6 Unknown none given no 
7 Unknown none given no 
8 Unknown none given no 
10 Unknown none given no 
11 Unknown none given no 
14 Unknown none given no 
18 Unknown none given no 
19 Unknown White medium round colonies no 
20 Unknown none given no 
21 Unknown none given no 
24 Unknown none given no 
25 Unknown none given no 
26 Unknown none given no 
27 Unknown  Medium yellow, medium round colonies yes 
28 Unknown white/yellow small round colonies yes 
32 Unknown Medium yellow, medium round colonies yes 
36 Unknown none given no 
37 Unknown none given no 
38 Unknown none given no 
39 Unknown none given no 
43 Unknown none given no 
44 Unknown none given no 
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56 Unknown none given yes 
68 Unknown none given no 
83 Unknown none given no 
 
Table 3: Isolate information from 2016 
Number Genus Description Did it inhibit 
M. smegmatis 
1 Unknown None given no 
2 Unknown None given no 
3 Unknown None given no 
4 Unknown None given no 
5 Unknown None given no 
6 Unknown None given no 
7 Unknown None given no 
8 Unknown None given no 
10 Unknown None given no 
11 Unknown None given no 
12 Unknown None given no 
13 Unknown None given no 
14 Unknown None given no 
15 Unknown None given no 
16 Enterobacter or 
Raoultella 
small white colonies, grows in large clumps yes 
17 Unknown None given no 
18 Unknown None given no 
19 Unknown None given no 
20 Unknown None given no 
21 Unknown None given no 
22 Unknown white small round colonies yes 
23 Unknown None given no 
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Appendix B: Agar plate Protocol 
  
1)  20 g dry LB agar powder 
2)  500 ml distilled water 
3)  Stir rod 
4)  500 ml beaker 
5)  Empty petri dishes 
  
  
20 g of dry agar powder was weighed out and poured into a 500 ml beaker containing a stir rod. 
The beaker was then filled with 500 ml of distilled water, and contents were mixed using a stir 
plate until the mixture was smooth and contained no clumps. The mixture was then autoclaved 
for 30 minutes at 120°C to sanitize and destroy any bacteria. The hot agar mix was then poured 
into individual petri dishes, covered, and left for 1 hour at room temperature. After cooling, 
plates were stored in a 4°C refrigerator until needed. 
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Appendix C: M. smegmatis and Bacterial Isolates Stock Plates Protocol  
  
1)  200µl M. smegmatis aliquot 
2)      Bacterial isolates (previously plated) (Microbes to Molecules) 
3)  LB agar plates 
4)  Plate spreader 
5)  Ethanol 
6)  Inoculation loop 
  
Stocks of M. smegmatis and the bacteria from the Small World lab were taken from previously 
prepared frozen aliquots to create personal stocks for use in this project. A sterilized metal 
bacteria spreader was dipped in 70% ethanol and dried with a kimwipe to sterilize.  It was then 
used to spread 200µl of M. smegmatis onto a previously prepared agar plate, and the plate was 
set aside to dry. A flame sterilized inoculation loop was then used to lift bacteria from previously 
prepared Small World bacteria plates and then spread onto agar plates, which were sectioned and 
numbered on the outside with permanent marker. The loop was flame sterilized between each 
bacteria spread. These plates, including the M. smegmatis plate, were stored in a 37°C for 3 days 
and then moved into a 4°C refrigerator until needed. 
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Appendix D: M. smegmatis Aliquot Stocks Protocol  
  
1)  M. smegmatis Plate 
2)  20 ml 7H9 + Tween Medium 
3)  Inoculation loop 
4)  1.5 ml eppendorf tubes 
  
Liquid cultures of M. smegmatis was grown and stored for easier plating and experimentation. 
To do this, a flame sterilized inoculation loop was used to lift several colonies off the plate 
containing grown M. smegmatis and gently mixed into the 7H9 + Tween medium. This mixture 
was then stored in a 37°C shaker overnight until the optical density (OD) of the bacteria was 
about 0.7.  Once this OD was reached the mixture was separated into 1.5 ml eppendorf tubes, 
labeled, and stored in a -80°C freezer. 
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Appendix E: M. smegmatis and Bacterial Isolates Inhibition Plates 
protocol 
  
1)  M. smegmatis aliquots 
2)      Bacterial isolates plates (Microbes to Molecules) 
3)  LB agar plates 
4)  Plate spreader 
5)  Ethanol 
6)  Inoculation loop 
  
  
To determine which of the mystery bacteria successfully inhibit the growth of M. smegmatis, the 
bacteria was plated together with the M. smegmatis. To do this, agar plates were spread with 
200µl each of the aliquoted M. smegmatis using a plate spreader (sterilized with ethanol) and 
allowed to dry for 5 minutes. Once dry, a flame sterilized inoculation loop was used to lift 
colonies of the mystery bacteria from the stock plates and spread on top of the dry M. smegmatis. 
These plates were then stored in a 37°C incubator for 3 days and then viewed. If there was a 
distinct empty space between the mystery bacteria and the lawn of M. smegmatis, it indicated the 
bacteria was successful in inhibiting M. smegmatis growth. 
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Appendix F: Colony PCR protocol 
 
1) Soil isolate streak plates 
2) Inoculation loop 
3) 1.5 mL  tubes 
4) Pipet and pipet tips 
5) Distilled water 
6) TAQ master mix (QIAGEN) 
7) 27 forward primer (IDT) 
8) 1492 reverse primer (IDT) 
9) Thermocycler 
 
The first step for colony PCR was to scrape several colonies of the bacteria into 0.2 mL PCR 
tubes containing 100µL of distilled water. This mixture was then boiled in the thermocycler at 
80℃ for 10-15 minutes. 12.5µL of TAQ master mix was added to four 0.2mL PCR tubes. 2 µL of 
each boiled sample was placed in their labeled PCR tube. 1µL of forward primer and 1µL of 
reverse primer was added to each solution. 8.5µL of distilled water was then added and the 
solutions were mixed by pipetting up and down several times. The samples were then moved to 
the thermocycler. The thermocycler was set up to run the PCR protocol for 33 cycles at 95℃ for 
30 seconds, 54℃ for 45 seconds, and 72℃ for 90 seconds, and a final hold at 4℃ until it was 
taken it out.   
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Appendix G: DNA Extraction Protocol 
 
10) Soil isolate streak plates 
11) Inoculation loop 
12) 1.5 mL eppendorf tubes 
13) Pipet and pipet tips 
14) Distilled water 
15) Cell suspension liquid * 
16) Cell lysis solution* 
17) Protein precipitation solution* 
18) Isopropanol 
19)  70% ethanol 
20)  Heat block 
21)  Centrifuge 
22)  Room temperature shaker 
*provided by QIAGEN 
 
DNA extraction was completed following an adaptation of the protocol provided by the Gentra 
puregene kit produced by QIAGEN. Using a 200µL pipet tip several colonies of a bacteria was 
scraped and mixed, by pipetting up and down, into 300µL of Cell Suspension Solution in a clean 
1.5 mL eppendorf tube. This solution was then centrifuged for 1 minute at 14,000 x g. The 
supernatant was discharged into a waste beaker. Then 300µL of Cell Lysis Solution was pipetted 
up and down to lyse the cells in the pellet. The sample was incubated at 80℃ for 5 minutes in the 
heat block. The sample was then put on ice for 1 minute to quickly cool the sample. 100µL of 
Protein Precipitation Solution was added then the solution was vortexed for 20 seconds at high 
speed. The sample was then centrifuged for 3 minutes at 14,000 x g. 300µL of isopropanol was 
pipetted into a new 1.5 mL eppendorf tube. The supernatant from the previous tube was added by 
carefully pipetting. This was mixed by inverting gently 50 times. Then the new tube was 
centrifuged for 1 minute at 14,000 x g. The supernatant was discarded and the pellet of DNA was 
washed with 300 µL of 70% ethanol. The sample was centrifuged again for 1 minute at 14,000 x 
g. The supernatant was discarded and the pellet was dried for 5 minutes then 100µL of distilled 
water was added. The sample was vortexed and incubated at 65℃ for 1 hour to dissolve the 
DNA. The dissolved DNA sample was left on the room temperature shaker overnight. 
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Appendix H: DNA PCR Protocol 
 
1) 0.2 mL PCR tubes 
2) DNA extraction samples  
3) TAQ master mix (QIAGEN) 
4) 27 forward primer or sss969 forward primer (IDT) 
5) 1492 reverse primer or sss967 reverse primer (IDT) 
6) Distilled water 
7) Thermocycler 
 
In order to complete the PCR of the DNA that was extracted from the samples, the mixing 
proportions provided by QIAGEN was followed. 12.5µL of TAQ master mix was added to 4 
0.2mL PCR tubes. 2 µL of each sample was placed in their labeled PCR tube. 1µL of forward 
primer and 1µL of reverse primer was added to the solution. 8.5µL of distilled water was then 
added and the solution was mixed by pipetting up and down several times. The samples were 
then moved to the thermocycler. The thermocycler was set up to run the PCR protocol for 33 
cycles at 95℃ for 30 seconds, 44℃ for 45 seconds, and 72℃ for 90 seconds, and a final hold at 
4℃ until it was taken out.   
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Appendix I: Gel electrophoresis protocol 
 
1) Agarose powder (provided by Michael Buckholt) 
2) 1X TAE buffer 
3) 150 ml Erlenmeyer flask 
4) Gel tray 
5) Well comb 
6) Gel box 
7) Electrodes 
8) Voltage source 
9) PCR samples 
10) Hyperladder 
11) SYBR green 
 
In order to see if the PCR produced amplified DNA, gel electrophoresis was run on the samples. 
A 1% agarose gel was made by mixing 0.5 g of agarose powder with 50mL of 1X TAE Buffer in 
a 150 ml Erlenmeyer flask and microwaving until the powder dissolved. Once the flask cooled to 
the touch, the 1% agarose solution was poured into the gel tray with a well comb attached. The 
agarose solution was allowed to harden for 30 minutes at room temperature. The well comb was 
removed and the gel was repositioned in the gel box. Then 1X TAE buffer was poured into the 
gel box until it covered the agarose gel. The 6µL of the PCR sample was mixed with 1µL of 
SYBR green. The hyperladder was always loaded in lane 1 then the samples were loaded in the 
other lanes. The gel was run for 30 minutes at 100 volts. 
 
 
 
 
 
 
 
 
 
 
 
 30 
 
 
Appendix J: Secretion Extraction protocol 
 
Part 1 
1)  One plate of each soil isolate (4 total: 2014-3, 2015-1, 2015-27, 2016-16) 
2) 100 mL glass bottle with cap (1 per isolate) 
3) Microspatula 
4) Liquid nitrogen OR -80°C freezer 
5) Methanol 
6) 20 mL glass bottle (1 per isolate) 
7) Fume hood 
 
An extraction was performed in order to determine if the isolates had secretions that were the 
cause of M. smegmatis inhibition. One plate of each type of soil isolate was used, grown 
previously on LB agar. Each plate had a dense lawn of isolates. A microspatula was used to cut 
the plate into small pieces (about 1 Cm2). All pieces were scooped into labeled 100 mL glass 
bottle (a separate bottle for each isolate). The bottles were frozen in liquid nitrogen; alternatively, 
bottles can be frozen overnight in a  -80°C freezer. After freezing, 12 mL of methanol was added 
to each bottle in a fume hood. The bottle was capped and placed on shaker at room temperature 
for 48 hours. The extract was then allowed to dry down via evaporation (uncapped bottle in fume 
hood).  
 
Part 2 
1) Dried-down extract in glass bottle (1 per isolate) 
2) Media plates (LB agar) 
3) M. smegmatis culture 
4) Methanol 
5) Filter disks (autoclaved) 
6) Rifampin (Concentrations of 50 mg/ml, 10 mg/ml and 1 mg/ml) 
7) DMSO (negative control) 
8) Sterile 15 mL test tube 
9) Micropipette and tips (P20 and P200) 
 
Dried-down extracts were resuspended in 80µL of methanol. Four agar plates were spread with 
200µL of M. smegmatis and allowed to dry for 3-5 minutes. Plate one was divided into quarters; 
the first quarter was given a filter disk soaked with 30 ml Rifampin at 50 mg/ml concentration, 
the second quarter was given a filter disk soaked with 30 ml Rifampin at 10 mg/ml 
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concentration, the third quarter was given a filter disk soaked with 30 ml Rifampin at 1 mg/ml 
concentration, and the fourth quarter was left with only M. smegmatis. Plate two was divided in 
half; the first half was given a filter disk soaked with methanol, and the second half was given a 
filter disk soaked with DMSO. Plate three was divided in half; the first half was given a filter 
disk soaked with resuspended extract from 2014-3, and the second half was given a filter disk 
soaked with resuspended extract from 2016-16. Plate four was divided in half; the first half was 
given a filter disk soaked with resuspended extract from 2015-1, and the second half was given a 
filter disk soaked with resuspended extract from 2015-27. The plates were labeled and incubated 
at 37°C for 3 days. Plates were then observed for zones of inhibition.  
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Appendix K: sequences of isolates 
 
Isolate sequence 
2014-3 
Sequencing 
primer: 
sss967  
 
TACCTATCCCTCTTTTAGCGGCTCATTTCTTACGCTGTAACCGGGCTGGCTGCCTGTCC
ACGACCGACGCCCATTGACGA 
AAGACACTTATGAAGGTAATGTAACGTCGCAGTTCGATGCGTCCCATTTCCCATTATT
GACTATAGCGGACGGTGCCTGC 
GATTGATATGACGCCTCCTTTATATAATTCCACCACTAAACCACGCCACTCAGTTAGA
TGTCCCCCAGTAATTACCTACG 
CTATTTGGATTAAAAAAAGTTAATGTCAGTTAGGGGTTGGGGCGGGCGGTGCGGCGA
TTCTCGGGGCTGCAACATTAAAG 
TTGTTTTGTATGCAAGACCAACTCGACCTCCCTTTGTAATATTTTATTAGTTAAAATGG
CTAATAGCCATGAGAAAACTT 
TAGCCTTGTTTTAGCCCTAGA 
 
2015-1 
Sequencing 
primer: 
27F 
 
NNATGGCGAGCGAGCATCATACATGCAGTCGAGCGAATGGATTGAGAGCTTGCTCTC
ATGAAGTTAGCGGCGGACGGGTG 
AGTAACACGTGGGTAACCTGCCCATAAGACTGGGATAACTCCGGGAAACCGGGGCTA
ATACCGGATAACATTTTGAACTG 
CATGGTTCGAAATTGAAAGGCGGCTTCGGCTGTCACTTATGGATGGACCCGCGTCGC
ATTAGCTAGTTGGTGAGGTAACG 
GCTCACCAAGGCAACGATGCGTAGCCGACCTGAGAGGGTGATCGGCCACACTGGGAC
TGAGACACTACAAAAAACTTATA 
CGGGAGGCAGCAGTAGGGAATCTTCCGCAATGGACGAAAGTCTGACGGAGCAACGC
CGCGTGAGTGATGAAGGCTTTCGG 
GTCGTAAAACTCTGTTGTTAGGGAAGAACAAGTGCTAGTTGAATAAGCTGGCACCTT
GACGGTACCTAACCAGAAAGCCA 
CGGCTAACTACGTGCCAGCAGCCGCGGTAATACGTAGGTGGCAAGCGTTATCCGGAA
TTATTGGGCGTAAAGCGCGCGCA 
GGTGGTTTCTTAAGTCTGATGTGAAAGCCCACGGCTCAACCGTGGAGGGTCATTGGA
AACTGGGAGACTTGAGTGCAGAA 
GAGGAAAGTGGAATTCCATGTGTAGCGGTGAAATGCGTAGAGATATGGGAGGAACA
CCAGTGGCGAAGGCGACTTTCTGG 
TCTGTAACTGACACTGAGGCGCGAAAGCGTGGGGGAGCAAACAGGATTAGATACCCT
GGTAGTCCACGCCGTAAACGATG 
AGTGCTAAGTGTTAGAGGGTTTCCGCCCTTTAGTGCTGAAGTTAACGCATTAAGCACT
CCGCCTGGGGAGTACGGGCCGC 
AAGGCTGAAACTCAAAGGGAATTGACGGGGGCCCGGCACAAGCGGTGGAGCATGTG
GTTTAAATCCGAAGCAACGCGAAG 
AACCTTACCAGTCTTGACATCCTCTGAAACCTAGAGATAGGGCTTCTCTTCGGGAGCA
GAGGAAGGGGGGTGCATGGTGT 
CGTCAGCTCGGGCCGGAGGAAGTTGGGATAGGTCCGCGAACGAGCGCCACCCTTTGA
TCTTATGCAATCTTAAATGGCAC 
TNCTAAGAGGGACGGCGGGATG 
 
2015-27 CGCTTTCAGCTTTTTTAGGGCATCGAAGTGTCGTCCCTCGACATGTGTTCTTTTGTCCA
CTCTTTTGATGCCTTTCCAGC 
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Sequencing 
primer: 
27F 
 
AGGAAAGTCTATCCGGTGTGTACTGGCCATAATGCCATGCATCCCCTTTAACGTAATT
GACGTCAATACGGTGGGTACTT 
TTCATATGATAAACTAGATGTCCTGAAAATTTATCAGTTCACCTTGATACTCCACCCA
TTGACGTTTTGGAATGCCCTAT 
TGCAGTGGTGTAGGATATACCTCCTTATTTTCGCCAATGGGCGGGGGTCGTCCTTCTT
CAGGAAAGCGCTCCATTTACCT 
TATGCGATGTAACGGACTCTAACTCTAACCAACTCCATCCCCTGCTCATTGTGTGTTA
TGGAGAGGGGGCCTTTTTCATA 
TGATTCCTTCATAGTTGTTTATTTC 
2016-16 
Sequencing 
primer: 
27F 
 
NGNAGTGGCGGCAGGTCTACACATGCAGTCGAGCGGTAGCACAGAGAGCTTGCTCTC
GGGTGACGAGCGGCGGACGGGTG 
AGTAATGTCTGGGAAACTGCCTGATGGAGGGGGATAACTACTGGAAACGGTAGCTAA
TACCGCATAACGTCGCAAGACCA 
AAGTGGGGGACCTTCGGGCCTCATGCCATCAGATGTGCCCAGATGGGATTAGCTAGT
AGGTGGGGTAATGGCTCACCTAG 
GCGACGATCCCTAGCTGGTCTGAGAGGATGACCAGCCACACTGGAACTGAGACACGG
TCAAAACACCTACGGGAGGCAGC 
AGTGGGGAATATTGCACAATGGGCGCAAGCCTGATGCAGCCATGCCGCGTGTATGAA
GAAGGCCTTCGGGTTGTAAAGTA 
CTTTCAGCGAGGAGGAAGGCGTTAAGGTTAATAACCTTGGTGATTGACGTTACTCGC
AGAAGAAGCACCGGCTAACTCCG 
TGCCAGCAGCCGCGGTAATACGGAGGGTGCAAGCGTTAATCGGAATTACTGGGCGTA
AAGCGCACGCAGGCGGTCTGTCA 
AGTCGGATGTGAAATCCCCGGGCTCAACCTGGGAACTGCATTCGAAACTGGCAGGCT
AGAGTCTTGTAGAGGGGGGTAGA 
ATTCCAGGTGTAGCGGTGAAATGCGTAGAGATCTGGAGGAATACCGGTGGCGAAGGC
GGCCCCCTGGACAAAGACTGACG 
CTCAGGTGCGAAAGCGTGGGGAGCAAACAGGATTAGATACCCTGGTAGTCCACGCCG
TAAACGATGTCGACTTGGAGGTT 
GTGCCCTTGAGGCGTGGCTTCCGGAGCTAACGCGTTAAGTCGACCGCCTGGGGGAGT
ACGGCCGCAAGGTTAAAACTCAA 
ATGAATTGACGGGGGCCCGCACAAGCGGTGGAGCATGTGGTTTAATTCGATGCAACG
CGAAGAACCCTTACCTACTCTTG 
ACATCCAGAGACTTAGCAGAGATGCTTTGGTGCCTTCGGGAACTCTGAGACAGGTGC
TGCATGGCTGTCGTCAGCTCGTG 
TTGTGAAATGTGGGGTAAGTCCCGCAACGAGCGCCACTCTTATCTTTGTGGCAGCGGT
CGGCCGGACTCAAAGGAGACTG 
CAGTGGATAACTGANAAGTGNTGACGTCAGGTCATCATGGCNTACGAGTAGGGCTAT
CACACGTGCTACATGCATTACAA 
AGAAGGNNGC 
 
 
 
 
 
 
 34 
Bibliography 
 
Akinola RO. A Systems Level Comparison of Mycobacterium tuberculosis, 
Mycobacterium leprae and Mycobacterium smegmatis Based on Functional Interaction 
Network Analysis. Journal of Bacteriology & Parasitology. 2013;04(04). 
 
Alam MA, Arora K, Gurrapu S, Jonnalagadda SK, Nelson GL, Kiprof P, Jonnalagadda 
SC, Mereddy VR. Synthesis and evaluation of functionalized benzoboroxoles as potential 
anti-tuberculosis agents. Tetrahedron. 2016;72(26):3795–3801.  
 
Barbier M, Wirth T. The evolutionary history, demography, and spread of the 
mycobacterium tuberculosis complex. microbiolspec. 2016;4(4). 
 
Calligaro GL. Drug-resistant tuberculosis. CME: Your SA Journal of CPD. 2013;31(9). 
 
Drug-Resistant TB. Centers for Disease Control and Prevention. 2016 May . 
https://www.cdc.gov/tb/topic/drtb/ 
 
Handayuthapani  S1, Zhang Y, Mudd MH. 1996. Oxidative stress response and its role in 
sensitivity to isoniazid in mycobacteria: characterization and inducibility of ahpC by 
peroxides in Mycobacterium smegmatis and lack of expression in M. aurum and M. 
tuberculosis.. PubMed (3641-9) 
 
Henkel JS, Baldwin MR, Barbieri JT. Toxins from bacteria. Experientia Supplementum 
Molecular, Clinical and Environmental Toxicology. 2010:1–29. 
 
Hibbing ME, Fuqua C, Parsek MR, Peterson SB. Bacterial competition: surviving and 
thriving in the microbial jungle. Nature Reviews Microbiology. 2009;8(1):15–25. 
 
Kalab M. Mycobacterium smegmatis. Mycobacterium smegmatis. 2007 May [accessed 
2016 Oct 3]. http://www.usu.edu/westcent/microstructure_food/myco-smegma.htm 
 
Ling Lin P, Flynn JAL. Understanding Latent Tuberculosis: A Moving Target. The 
Journal of Immunology. 2010;185(1):15–22. 
 
Lubran MM. Bacterial toxins. Annals of Clinical & Laboratory Science. 1988;18(1):58–
71. 
 
 35 
Olejníková P, Kurucová M, Švorc LU, Marchalín Š. Induction of resistance in 
Mycobacterium smegmatis. Canadian Journal of Microbiology. 2013;59(2):126–129.  
 
Pawlowski A, et al. Tuberculosis and HIV co-infection. PLoS Pathogens. 2012;8(2). 
 
Rozwarski DA, Grant GA, Barton DHR, Jacobs WIR, Sacchettini JC. Modification of the 
NADH of the Isoniazid Target (InhA) from Mycobacterium Tuberculosis. Science. 
1998;279:98–102. 
 
Sharma P, Kumar B, Gupta Y, Singhal N, Katoch VM, Venkatesan K, Bisht D. 
Proteomic Analysis of Streptomycin Resistant and Sensitive Clinical Isolates of 
Mycobacterium Tuberculosis. Proteome Science . 2010;8(1). 
Silve G, Valero-Guillen P, Quemard A, Dupont MA, Daffe M, Laneelle G. Ethambutol 
inhibition of glucose metabolism in mycobacteria: a possible target of the drug. 
Antimicrobial Agents and Chemotherapy. 1993;37(7):1536–1538. 
 
Wang X, Grace PM, Pham MN, Cheng K, Strand KA, Smith C, Li J, Watkins LR, Yin H. 
Rifampin inhibits Toll-like receptor 4 signaling by targeting myeloid differentiation 
protein 2 and attenuates neuropathic pain. The FASEB Journal. 2013;27(7):2713–2722. 
 
World Health Organization. Global Tuberculosis report. 20th ed. Geneva, Switzerland: 
World Health Organization; 2015. 
 
Zumla A1 A1, Chakaya  J2, Centis R3, D'Ambrosio L3, Mwaba P4, Bates M4, Kapata 
N5, Nyirenda T6, Chanda D4, Mfinanga S7, Hoelscher M8, Maeurer M9, Migliori GB3.. 
2015 Mar 9. Tuberculosis treatment and management--an update on treatment regimens, 
trials, new drugs, and adjunct therapies. 220-34. U.S National Library of 
Medicine:PubMed; [cited 2016 Sept 28] .  
 
  
 
